FY2029 Earnings Estimate for VRDN Issued By Leerink Partnrs

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Investment analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for shares of Viridian Therapeutics in a research note issued to investors on Monday, January 27th. Leerink Partnrs analyst T. Smith expects that the company will post earnings per share of $3.00 for the year. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). The company had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.08 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%.

A number of other equities analysts have also recently commented on VRDN. Royal Bank of Canada raised their target price on Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Tuesday, December 17th. Needham & Company LLC restated a “buy” rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, January 7th. HC Wainwright reiterated a “buy” rating and set a $34.00 target price on shares of Viridian Therapeutics in a report on Monday, December 16th. TD Cowen initiated coverage on shares of Viridian Therapeutics in a research note on Monday, November 25th. They issued a “buy” rating for the company. Finally, Wells Fargo & Company reiterated an “equal weight” rating and issued a $27.00 price objective (down from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.70.

Viridian Therapeutics Stock Up 1.6 %

NASDAQ:VRDN opened at $19.21 on Tuesday. Viridian Therapeutics has a 52 week low of $11.40 and a 52 week high of $27.20. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. The stock’s fifty day moving average is $19.43 and its two-hundred day moving average is $19.39. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of -4.46 and a beta of 1.13.

Institutional Trading of Viridian Therapeutics

Institutional investors have recently modified their holdings of the business. R Squared Ltd acquired a new stake in shares of Viridian Therapeutics in the 4th quarter worth approximately $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Viridian Therapeutics in the third quarter valued at $149,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Viridian Therapeutics in the third quarter valued at $208,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Viridian Therapeutics by 17.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company’s stock worth $318,000 after buying an additional 2,036 shares during the last quarter. Finally, AlphaCentric Advisors LLC boosted its position in shares of Viridian Therapeutics by 20.0% in the 3rd quarter. AlphaCentric Advisors LLC now owns 15,000 shares of the company’s stock worth $341,000 after buying an additional 2,500 shares in the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.